These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 215562)

  • 1. Correlated expression of a B-lymphocyte-specific glycoprotein (gp27/35) and the EBV receptor/C3 receptor complex in sublines from the same Burkitt lymphoma.
    Klein G; Hyman R; Trowbridge I
    Int J Cancer; 1979 Jan; 23(1):37-41. PubMed ID: 215562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between Epstein-Barr virus (EBV)-production and the loss of the EBV receptor/complement receptor complex in a series of sublines derived from the same original Burkitt's lymphoma.
    Klein G; Yefenof E; Falk K; Westman A
    Int J Cancer; 1978 May; 21(5):552-60. PubMed ID: 207646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysis of P3HR-1 cells induced to enter the viral cycle by antibody-dependent and independent immunological mechanisms.
    Kurakata S; Ramos OF; Klein G; Klein E
    Cell Immunol; 1989 Oct; 123(1):134-47. PubMed ID: 2550147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the B lymphoblast antigen No. 1 (BB-1) on a series of Burkitt lymphoma lines differing in the expression of the EBV/C3 receptor complex.
    Ehlin-Henriksson B; Clark EA; Jønsson V; Klein G
    J Immunol; 1983 May; 130(5):2448-52. PubMed ID: 6187858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
    Klein G; Ehlin-Henriksson B; Schlossman SF
    J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fc and C3 receptor patterns on two EBV- negative Burkitt lymphoma lines during acute exposure to EBV (P3HR-1 substrain).
    Jønsson V; Klein G
    Eur J Cancer (1965); 1981 Feb; 17(2):161-5. PubMed ID: 6266834
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation and fixation of C3 by human B cell lines is enhanced by interferon-gamma and tumor necrosis factor alpha.
    Yefenof E; Algarra I; Ramos OF; Klein E
    Complement Inflamm; 1991; 8(5-6):271-80. PubMed ID: 1666351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Membrane receptor stripping confirms the association between EBV receptors and complement receptors on the surface of human B lymphoma lines.
    Yefenof E; Klein G
    Int J Cancer; 1977 Sep; 20(3):347-52. PubMed ID: 198382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection.
    Klein G; Giovanella B; Westman A; Stehlin JS; Mumford D
    Intervirology; 1975; 5(6):319-34. PubMed ID: 181343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Column separation of viral capsid antigen (VCA)-positive cells from VCA-negative cells in an Epstein-Barr virus (EBV)-producing lymphoid line,
    Dalianis T; Klein G; Andersson B
    Int J Cancer; 1977 Apr; 19(4):460-7. PubMed ID: 191413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surface glycoprotein patterns of normal and malignant human lymphoid cells. II. B cells, B blasts and Epstein-Barr virus (EBV)-positive and -negative B lymphoid cell lines.
    Nilsson K; Andersson LC; Gahmberg CG; Wigzell H
    Int J Cancer; 1977 Nov; 20(5):708-16. PubMed ID: 200571
    [No Abstract]   [Full Text] [Related]  

  • 12. Persistence of transforming and nontransforming Epstein-Barr virus in high passages of P3HR-1 cell lines.
    Gerber P; Ablashi D; Magrath I; Armstrong G; Andersen P; Trach L
    J Natl Cancer Inst; 1982 Sep; 69(3):585-90. PubMed ID: 6287082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of the BLA antigen, defined by the monoclonal 38.13 antibody, on Burkitt lymphoma lines, lymphoblastoid cell lines, their hybrids and other B-cell lymphomas and leukemias.
    Klein G; Manneborg-Sandlund A; Ehlin-Henriksson B; Godal T; Wiels J; Tursz T
    Int J Cancer; 1983 May; 31(5):535-42. PubMed ID: 6303966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Epstein-Barr virus receptor is distinct from the C3 receptor.
    Wells A; Koide N; Stein H; Gerdes J; Klein G
    J Gen Virol; 1983 Feb; 64 (Pt 2)():449-53. PubMed ID: 6300295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative comparison of Epstein-Barr virus receptor expression on sIgM and sIgG cell lines and B-cell lymphoma biopsies.
    Wells A; Godal T; Kvaløy S; Steen HB; Klein G
    Differentiation; 1982; 22(2):113-9. PubMed ID: 6290303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.
    McConnell I; Klein G; Lint TF; Lachmann PJ
    Eur J Immunol; 1978 Jul; 8(7):453-8. PubMed ID: 211040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-evaluation of a transforming strain of Epstein-Barr virus from the Burkitt lymphoma cell line, Jijoye.
    Sairenji T; Hinuma Y
    Int J Cancer; 1980 Sep; 26(3):337-42. PubMed ID: 6270005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
    Masucci MG; Torsteindottir S; Colombani J; Brautbar C; Klein E; Klein G
    Proc Natl Acad Sci U S A; 1987 Jul; 84(13):4567-71. PubMed ID: 3037521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.
    Torsteinsdottir S; Masucci MG; Ehlin-Henriksson B; Brautbar C; Ben Bassat H; Klein G; Klein E
    Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5620-4. PubMed ID: 3016710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymphocytes stimulated by allogeneic B cell lines cleave the third component of complement and fix C3 fragments. Their nonspecific lytic capacity is elevated against complement receptor type 2-carrying targets.
    Ramos OF; Algarra I; Sármay G; Yefenof E; Gergely J; Klein E
    J Immunol; 1989 Jan; 142(1):217-23. PubMed ID: 2521233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.